Novel overactive bladder agent found efficacious, well tolerated

Article

The investigational selective beta3-adrenoceptor agonist mirabegron effectively improves symptoms of overactive bladder and is very safe and well tolerated.

Key Points

Washington-The investigational selective beta3-adrenoceptor agonist mirabegron effectively improves symptoms of overactive bladder and is very safe and well tolerated, according to results of a North American phase III study presented at the AUA annual meeting in Washington.

Using data from patient diaries, change from baseline to final visit in the mean number of incontinence episodes/24 hours and micturitions/24 hours were analyzed as co-primary efficacy endpoints. The results for both variables showed statistically significant differences favoring both mirabegron, 50 mg, and 100 mg over placebo (incontinence: –1.47 and –1.63 vs. –1.13; micturition frequency: –1.66 and –1.75 vs. –1.05).

Related Videos
Dr. Mehmet Asim Bilen in an interview with Urology Times
Anne M. Suskind, MD, MS, FACS, FPMRS, answers a question during a Zoom video interview
blurred clinic hallway
Female doctor using laptop | Image Credit: © nenetus - stock.adobe.com
Kathryn Marchetti, MD, answers a question during a Zoom video interview
Dr. Mayer Fishman in an interview with Urology Times
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.